The specific BTK inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B-cells with CD20 antibodies

Josée Golay, Greta Ubiali, and Martino Introna

Disclosures: JG has received the drugs ACP and IBT, as well as some research funding, from Acerta Pharma, San Carlos, CA. In the last 3 years, she has also received research funding and consultancy from Roche-Glycart, the firm that has developed obinutuzumab, used in this study.

Contributions: JG has planned and supervised the experiments. She has written the manuscript. GU has performed the work and analysed the data. MI has provided funding, has supervised the study and critically revised the manuscript.